NT
Intellia Therapeutics, Inc.
NTLA · NASDAQ
$13.07 +3.73% (+$0.47)
1M +10.11%
Market Cap $1.83B
P/E Ratio -
Div. Yield -
ROE 57.79%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
38 /100
Fair P/S 30.69x
P/B 2.51x
P/E N/A
Growth
49 /100
Stable Rev. growth 9.09%
Book val. growth 18.40%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 46.48%
FCF margin 783.30%
Net margin 672.16%
Quality
1 /100
Poor ROIC 52.86%
Asset turnover 0.07x
ROE 57.79%
Debt
100 /100
Low Debt/Equity 0.10x
Current ratio 6.65x
Int. coverage N/A
Stability
33 /100
Unstable Beta 1.80x
Profitable years 0
Rev. volatility 45.00%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NTLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Leonard
Employees
377
Headquarters
Cambridge
Upcoming events
05 NOV
Earnings
Upcoming earnings report